Email

weborders@prabadincorp.com

Call us

+1 (786)-332-3938
Drug Test
  • February 21, 2025

Individual identification method using samples associated with doping tests: A comparison of mitochondrial and nuclear genetic data

DNA analysis is used to detect attempts at manipulating or substituting samples during doping control. To determine a suitable method,…
Drug Test
  • February 21, 2025

Why the racing industry and equestrian disciplines need to implement population pharmacokinetics: To learn, explain, summarize, harmonize, and individualize

Population pharmacokinetics (POP PK) is a pharmacokinetic tool, which measures and explains the variability in drug exposure and drug effect…
Drug Test
  • February 21, 2025

Metabolism of highly potent synthetic opioid nitazene analogs: N‐ethyl‐N‐(1‐glucuronyloxyethyl) metabolite formation and degradation to N‐desethyl metabolites during enzymatic hydrolysis

This study revealed that nitazene analogs were mainly metabolized by N-1-hydroxylation followed by glucuronidation, N-deethylation, O-dealkylation followed by glucuronidation, and…
Drug Test
  • February 21, 2025

Urinary metabolites indicative of the administration of hypoxen monitored by liquid chromatography–high resolution/accurate mass tandem mass spectrometry

First data on suitable urinary markers indicative of the administration of the poly(dihydroxyphenylene) thiosulfonate-based drug hypoxen were generated, which can…
Drug Test
  • February 21, 2025

Cover Picture

compounding:-inspections,-recalls,-and-other-actions Drug Test
  • February 20, 2025

Compounding: Inspections, Recalls, and other Actions

Human drug compounding; FDA inspections; compounding recalls
safety-clinical-trial-shows-possible-increased-risk-of-cancer-with-weight-loss-medicine-belviq,-belviq-xr-(lorcaserin) Drug Test
  • February 20, 2025

Safety clinical trial shows possible increased risk of cancer with weight-loss medicine Belviq, Belviq XR (lorcaserin)

A safety clinical trial shows a possible increased risk of cancer with the weight-loss drug Belviq, Belviq XR. Consider the…
fda-strengthens-warning-that-untreated-constipation-caused-by-schizophrenia-medicine-clozapine-(clozaril)-can-lead-to-serious-bowel-problems Drug Test
  • February 20, 2025

FDA strengthens warning that untreated constipation caused by schizophrenia medicine clozapine (Clozaril) can lead to serious bowel problems

FDA warns that untreated constipation caused by schizophrenia drug clozapine (Clozaril) can get worse and lead to serious bowel problems…
fda-requests-the-withdrawal-of-the-weight-loss-drug-belviq,-belviq-xr-(lorcaserin)-from-the-market Drug Test
  • February 20, 2025

FDA requests the withdrawal of the weight-loss drug Belviq, Belviq XR (lorcaserin) from the market

FDA has requested that the weight-loss drug Belviq, Belviq XR be withdrawn from the U.S. market because a safety clinical…
fda-requires-boxed-warning-about-serious-mental-health-side-effects-for-asthma-and-allergy-drug-montelukast-(singulair);-advises-restricting-use-for-allergic-rhinitis Drug Test
  • February 20, 2025

FDA requires Boxed Warning about serious mental health side effects for asthma and allergy drug montelukast (Singulair); advises restricting use for allergic rhinitis

FDA requires a Boxed Warning about serious mental health side effects for the asthma & allergy drug Singulair (montelukast). Only…